Recent Advances in Drugs for Mitochondrial Diseases

Share this:
Published: 9 Jun 2017

Mitochrondrial diseases arise when there is a malfunctioning mitochondria. These diseases are sometimes cause by genetic anomalies and can also be acquired hereditarily. While some mitocondrial disorders affect only a single organ such as Leber hereditary optic neuropathy (LHON), there are others that can result in problems across multiple organs. However, extensive research is taking place for treating these rare disease, with multiple starts up receiving funding for their efforts in gene therapy, cellular therapy, and small molecule therapeutics. The Drug Discovery TechVision Opportunity Engine (TOE) reports and analyzes about the latest developments in drug discovery and therapeutics, thereby providing an opportunity to acquire strategic insights into crucial developments in this industry domain. Technologies profiled include those used for biomarker and target discovery such as high throughput screening, signal transduction, micro array, RNAi, metabolomics, toxicogenomics, biosensors and nanotechnology. In addition to these, a fair focus shall be dedicated to the latest trends in therapeutic approaches across a diversity of diseases including infectious, genetic, metabolic, neurological, cardiac, and autoimmune disorders. The Health and Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Mitochondrial disorder, mitochondria, small molecule therapeutics


Features of this research


Help Desk

Full list of offices

For more information and general enquiries, contact Frost & Sullivan near you.

North America
tel: +1.877.463.7678

Select a location near you..